Article

Zealand Pharma has entered a binding agreement with DCAI to utilize the Gefion AI supercomputer, Denmark's most powerful computing facility, to enhance its drug discovery efforts targeting metabolic diseases. The collaboration aims to integrate advanced protein-peptide simulations into existing peptide research, supporting Zealand Pharma's 'Metabolic Frontier 2030' strategy, which includes five product launches and over ten clinical pipeline programs by 2030.

The high-performance computing capabilities are expected to reduce cycle times from initial drug concepts to clinical testing. Attention is now on the J.P. Morgan Healthcare Conference from January 12-15, where CEO Adam Steensberg will present updates on late-phase clinical candidates and strategic milestones. Despite current stock trends showing a decline, the consensus among 15 analysts remains positive with an average price target of 745.93 DKK.